Shots:

• The approval is based on two study results assessing Revcovi in patients and demonstrated in an increase in ADA activity- reduction in concentration of toxic metabolites with an improvement in total lymphocyte counts
• Leadiant Biosciences’ Revcovi has received FDA’s Fast Track- Priority Review & ODD designation on 7 Jun- 2017- 27 Jun- 2018 & 19 Mar- 2015 respectively
• Revcovi (elapegademase-lvlr) is a recombinant adenosine deaminase enzyme replacement therapy (ERT) indicated for ADA-SCID in pediatric and adult patients

Ref: Leadiant Biosciences | Image: Glassdoor